Tanir Tayfun, Orellana Marvin, Escalante Aster, Moraes de Souza Carolina, Koeris Michael S
Amgen Bioprocessing Center, Department of Biological Engineering and Management, Keck Graduate Institute, Henry E. Riggs School of Applied Life Sciences, Claremont, CA 91711, USA.
Pharmaceuticals (Basel). 2021 Sep 17;14(9):934. doi: 10.3390/ph14090934.
Within this first part of the two-part series on phage manufacturing, we will give an overview of the process leading to bacteriophages as a drug substance, before covering the formulation into a drug product in the second part. The principal goal is to provide the reader with a comprehensive framework of the challenges and opportunities that present themselves when developing manufacturing processes for bacteriophage-based products. We will examine cell line development for manufacture, upstream and downstream processes, while also covering the additional opportunities that engineered bacteriophages present.
在这个关于噬菌体制造的两部分系列文章的第一部分中,我们将概述制备作为药物的噬菌体的过程,然后在第二部分介绍将其制成药品的配方。主要目标是为读者提供一个全面的框架,以了解在开发基于噬菌体的产品制造工艺时所面临的挑战和机遇。我们将研究用于制造的细胞系开发、上游和下游工艺,同时也会涉及工程噬菌体带来的额外机遇。